Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...

PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading ...

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse events In comparison to placebo, treatment with REC-994 400 mg showed ...

Los Angeles—Artificial intelligence (AI)-based drug discovery continues to tout accelerated timelines and novel and effective treatments, yet today’s clinical success rates remain at a low 10%. On ...

Abstract: The paper describes recent improvements made to the structural recursion of the Data Funnel Interface. This end user interface organizes the raw data in a database table into a series of ...

Recursion Pharmaceuticals (NASDAQ:RXRX) on Tuesday announced topline results from its SYCAMORE Phase 2 trial for its most advanced candidate REC-994 in symptomatic cerebral cavernous malformation (CCM ...

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top-line results of ...

Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper, likely won’t satisfy many investors closely watching the AI drug ...

Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today announced that preclinical data for the company’s lead ...

Recursion Pharmaceuticals has seen a 35% increase in stock price, driven by investments from NVIDIA and Roche. Key pipeline projects target unmet needs in CCM, NF2, and Familial Adenomatous Polyposis, ...